Driving Innovation in Life Sciences: A Journey of Growth and Connection

In this AT-TV interview recorded at Advanced Therapies Week 2025, Emerson executives Michalle Adkins (Life Sciences Strategy Lead) and Nikki Bishop (VP of Marketing and Customer Experience for Life Sciences Software) discuss how the company is enabling the life sciences industry to advance manufacturing capabilities for cell and gene therapies.

Emerson's approach focuses on five core industry drivers: pipeline acceleration, real-time release, operational integrity, sustainable operations, and flexible manufacturing. These priorities shape the development of solutions designed to help biotechs and CDMOs reduce time to market, improve product consistency, and streamline regulatory compliance.

The team highlights their DeltaV Workflow Management tool, a SaaS-based digital workflow solution that recently won an IoT award. This platform helps organizations digitize paper-based processes early in development, enabling more efficient tech transfer, better data tracking, and readiness for commercial manufacturing. As more biotechs transition from manual systems, solutions like this simplify scaling and ensure data integrity across the product lifecycle.

AI also plays a growing role in manufacturing optimization. Emerson sees artificial intelligence not just in drug discovery, but increasingly as a tool for enhancing commercial manufacturing efficiency, drawing insights from production data to improve processes and outcomes.

Emerson's commitment to the life sciences community is reflected in their internal ethos, “Team Lifesavers,” symbolizing their mission to help deliver life-saving therapies faster and more reliably. With automation, digitization, and AI at the forefront, Emerson continues to support the industry’s evolution toward smarter, more agile manufacturing.